Covagen's Acquisition

Covagen was acquired by Cilag International on August 25, 2014.

Covagen develops bispecific FynomAbs by fusing its human Fynomer binding proteins to antibodies, resulting in therapeutics with novel modes of action and enhanced efficacy in the treatment of inflamma…

Articles about Covagen's Acquisition: